Prognostic evaluation and choice of second-line treatment for patients with advanced non-small-cell lung cancer

摘要: SUMMARY Patients with progressive disease after first-line treatment for advanced non-small-cell lung cancer have a limited life expectancy. In the second-line setting, better understanding of prognostic factors and availability score can contribute to sensible evaluation risks benefits associated treatment. We previously showed that prognosis patients receiving is significantly conditioned by gender, performance status, histology, stage, previous platinum use response A based on these allows classification into three categories. The simple calculate because all variables considered are routinely collected as part baseline clinical patients. For majority patients, in absence known molecular predictive factors, choice among drugs demonstrated efficacy s...